One of the immunotherapies that target immune checkpoints, represented by blockade of programmed cell death protein 1 (PD-1) and its ligand programmed death ligand 1 (PD-L1), has been approved for clinical treatment of RCC patients [3]. This evidence concerns the gene CD274 and renal cell carcinoma.